Browsing: Shield Therapeutics

In the first half of the year, Shield Therapeutics experienced over threefold revenue growth, reaching $12.1 million. The company focuses…

Shield Therapeutics has successfully gained approval from Health Canada for its ground-breaking Accrufer tablets. This development marks a significant step…

Shield Therapeutics has undergone a significant leadership change, marking a new chapter for the company. Greg Madison, who led the…

The North East has witnessed a series of noteworthy business deals and investments this week. Companies across various sectors are…

Shield Therapeutics has announced a significant financial agreement with its largest shareholder, AOP Health International Management, securing an advance of…